VTGN Stock Overview
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS).
VistaGen Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.13|
|52 Week High||US$2.11|
|52 Week Low||US$0.077|
|1 Month Change||5.81%|
|3 Month Change||-20.49%|
|1 Year Change||-92.71%|
|3 Year Change||-78.84%|
|5 Year Change||-88.88%|
|Change since IPO||-99.73%|
Recent News & Updates
|VTGN||US Biotechs||US Market|
Return vs Industry: VTGN underperformed the US Biotechs industry which returned -6.5% over the past year.
Return vs Market: VTGN underperformed the US Market which returned -17.6% over the past year.
|VTGN Average Weekly Movement||15.2%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: VTGN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: VTGN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company’s CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders.
VistaGen Therapeutics, Inc. Fundamentals Summary
|VTGN fundamental statistics|
Is VTGN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VTGN income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.31|
|Net Profit Margin||34,836.35%|
How did VTGN perform over the long term?See historical performance and comparison